208533-37-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloroquinazolin-6-amine is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic effects. It is particularly noted for its inhibitory effects on certain enzymes and cell growth, making it a candidate for the development of anticancer drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 4-chloroquinazolin-6-amine serves as a building block in the creation of various agrochemical compounds, contributing to the development of products that address agricultural needs.
Used in Specialty Chemicals Production:
4-Chloroquinazolin-6-amine is also investigated for its potential use as an intermediate in the production of dyes and other specialty chemicals, highlighting its versatility in different chemical applications.
Used in Cancer Treatment Research:
4-Chloroquinazolin-6-amine is utilized in research as a compound with potential cancer treatment capabilities. Its inhibitory effects on specific enzymes and cell growth are under investigation for the development of novel therapeutic agents against cancer.

InChI:InChI=1/C8H6ClN3.ClH/c9-8-6-3-5(10)1-2-7(6)11-4-12-8;/h1-4H,10H2;1H

Upstream product

• 19815-16-8 4-chloro-6-nitro-quinazoline 

Relevant academic research and scientific papers

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS

This invention provides compounds of formula (1) wherein X is C3-7 cycloalkyl, pyridinyl, pyrimidinyl or phenyl ring optionally substituted as described in claim 1, R1, R3 and R4 are chosen from the groups listed in claim 1. R2 is chosen from various unsaturated acyl groups listed in claim 1, with certain compounds being disclaimed. Use as tyrosine kinase inhibitors for the treatment of cancer and certain kidney diseases such as polycystic kidney disease.

USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE

This invention provides a method of treating or inhibiting polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal a compound having formula (1) wherein X is phenyl which is optionally substituted; R and R1 are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl; R2 is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl; Y is a radical selected from the group consisting of (a), (b), (c), (d), (e), (f) and (g); R3 is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n = 2-4; or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be the same or different.

Substituted quinazoline derivatives

This invention provides compounds of formula 1 having the structure wherein: X, R1, R2, R3, R4, Z, X, and n are as defined hereinbefore in the specification, which are useful as antineoplastic agents and in the treatment of certain kidney diseases, such as polycystic kidney disease.

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound having the formula wherein:X is phenyl which is optionally substituted;R and R1 are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl;R2 is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl;Y is a radical selected from the group consisting of R3 is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl;n=2-4;or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be the same or different.

Method of treating polycystic kidney disease

This invention provides a method of treating or inhibiting polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal a compound having the formula STR1 wherein: X is phenyl which is optionally substituted; R and R1 are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl; R2 is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl; Y is a radical selected from the group consisting of STR2 R3 is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n=2-4; or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be the same or different.